Phase 3 N=39 LutrePulse Hypogonadotropic Hypogonadism
Primary Amenorrhea With Hypogonadotropic Hypogonadism
Primary: Ovulation Rate — 1; 4; 5; 9 Participants — p=0.0120
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=24 Theca Cell Function in Adolescents With Polycystic Ovary Syndrome (PCOS)
PCOS
Primary: 17OHP Levels After hCG — 3.2; 1.3 ng/ml
Phase 2 N=20 Study of Leptin for the Treatment of Hypothalamic Amenorrhea
Amenorrhea
Primary: the Difference Between the Placebo and Leptin Treated Groups in the Change in Bone Mineral Content(BMC) at the Anteroposterior (AP) Spine From Baseline to 36 Weeks…
Phase 1 N=9 Opioid Antagonism in Hypogonadotropic Hypogonadism
Hypogonadotropic Hypogonadism · Low Testosterone
Primary: Average Change in Mean Luteinizing Hormone (LH) Value — 1.571 IU/L
Phase 2 N=59 GnRH Analogue for Ovarian Function Preservation in Hematopoietic Stem Cell Transplantation Patients
Amenorrhea · Premature Ovarian Failure · Ovarian Function Insufficiency
Primary: Number of Participants With Secondary Amenorrhea Following 3-month Depot Leuprolide — 37 participants
Phase 3 N=31 A Study Using Recombinant Human Luteinizing Hormone (r-hLH, Luveris®) in the Treatment of Chinese Women With Hypogonadotropic Hypogonadism
Hypogonadism
Primary: Number of Participants Who Met Both Index 1 and Index 2 — 23 participants
N/A N=62 Reproductive Hormonal Alterations in Obesity
Obesity
Primary: Changes in Luteinizing Hormone (LH) Pulse Amplitude (Aim 1) — 4.1; 3.6 IU/L
Early Phase 1 N=6 Investigation of Female Reproductive Hormone Dynamics During Adolescence
Menstruation Disturbances
Primary: Ovulation in Cycle 2 — 3; 2 Participants
Phase 4 N=20 Endocrine Dysfunction and Growth Hormone Deficiency in Children With Optic Nerve Hypoplasia
Growth Hormone Deficiency · Septo-Optic Dysplasia · Hypopituitarism
Primary: Change in Anthropometric Measures Over Time — 1.97; -0.61; 1.39; 1.22 Z-score
N/A N=25 Effect of Metformin on Sensitivity of the GnRH Pulse Generator to Suppression by Estradiol and Progesterone
Polycystic Ovary Syndrome · Hyperandrogenism
Primary: Change in Progesterone Sensitivity Index Before and After Metformin Treatment. — -4.12; -4.29 % change in LH pulses/day 7 P4 level
Phase 3 N=50 The Adrenal Contribution to Androgen Production in Girls During Puberty
Development
Primary: 17-hydroxyprogesterone Response to ACTH — 2.4; 3.7; 3.1; 2.9 ng/mL
Phase 3 N=35 Effects of Triptorelin Pamoate in Children With Precocious Puberty - Follow up Study
Precocious Puberty
Primary: Percentage of Children With a Stabilisation or Regression of Tanner Pubertal Stage at the End of the Study (Final Visit), Compared to Pretreatment (Month -6) and…
Phase 2 N=29 Atherosclerosis, Immune Mediated Inflammation and Hypoestrogenemia in Young Women
Estrogen Deficiency · Cardiovascular Disease (CVD) · Functional Hypothalamic Amenorrhea
Primary: Rate of Change of Reactive Hyperemia Index (RHI) by Peripheral Arterial Tonometry — 0.20; 0.25 change of RHI
N/A N=70 Intrauterine Environment in Polycystic Ovary Syndrome (PCOS) Probands
Polycystic Ovary Syndrome
Primary: Estradiol Level in Female Offspring — 18606; 6467 pg/ml — p=0.049
Phase 4 N=41 Estrogen Dosing in Turner Syndrome: Pharmacology and Metabolism
Turner Syndrome · Hypogonadism · Premature Ovarian Failure
Primary: Change in Weight From Baseline at 12 Months — 1.1; 1.9 kilograms
Phase 3 N=37 Efficacy and Safety Study of Pamoate of Triptorelin in Children With Precocious Puberty
Precocious Puberty
Primary: Number of Participants With a GnRH-stimulated LH Level ≤3 IU/L — 31; 6; 31; 3 participants
Phase 3 N=91 Somatropin + Leuprorelin vs Somatropin Alone in Pubertal Children With Idiopathic Short Stature
Idiopathic Short Stature (ISS)
Primary: Number of Participants With One or More Drug-related Adverse Events — 42; 38; 11; 9 participants
Phase 3 N=12 Metabolic and Neuro-Endocrine Effect of Treating PCOS in Adolescents
PCOS
Primary: Oral Glucose Tolerance Test — 0.9 mg/dL
Phase 3 N=80 Adrenal and Gonadal Hormone Replacement in Anorexia Nervosa
Anorexia Nervosa
Primary: Areal Bone Density by DXA — 0.88; 0.89 g/cm2
Phase 2 N=58 Lutropin Alfa in Women at Risk of Poor Response
Ovarian Stimulation
Primary: Number of Oocytes Retrieved — 4.0; 3.5 Oocytes
Phase 3 N=265 SJ-0021 (Gonalef®) Versus Purified Pituitary Gonadotropin (Fertinorm-P®) for Ovulation Induction in Japanese Infertile Women
Infertility · Ovulation Induction
Primary: Percentage of Participants With Ovulation — 79.1; 82.6 percentage of participants
Phase 3 N=19 Primary Ovarian Insufficiency: Phenotype and Optimal Treatment
Primary Ovarian Insufficiency
Primary: Change in Dual Energy X-ray Absorptiometry (DXA) Measure of Bone Mineral Density (BMD) of the Lumbar Spine — 0.228; 0.673 Z-score
N/A N=60 Dysregulation of FSH in Obesity: Functional and Statistical Analysis
Obesity · Fertility
Primary: Difference Between Peak Inhibin B — 100.8; 38.8 picograms/mL
Phase 2 N=53 The Effect of Hormonal Add-Back Therapy in Adolescents Treated With a GnRH Agonist for Endometriosis: A Randomized Trial
Endometriosis
Primary: Bone Mineral Density — 0.01; -0.11 g/cm^2 — p=0.10
Phase 1 N=34 Bioequivalence Trial of Liquid Versus Freeze-Dried Pergoveris® in Pituitary Suppressed Healthy Premenopausal Female Subjects
Healthy
Primary: Baseline Corrected Area Under the Concentration-Time Curve From Zero to Last Quantifiable Concentration (AUC 0-t,Adj) for Follicle-Stimulating Hormone (FSH) — 3187.4…
Phase 3 N=25 Theca Cell Function in Women With Polycystic Ovary Syndrome (PCOS)
Polycystic Ovary Syndrome
Primary: Serum 17OHP Responses to hCG — 2.0; 1.2; 1.1; 1.0 ng/ml — p=<0.05
Phase 2 N=36 Administration of Kisspeptin in Patients With Hyperprolactinemia
Hyperprolactinemia · Hypogonadism
Primary: Average Change in Number of Luteinizing Hormone (LH) Pulses Over 10 Hours — 3.000 pulses per 10 hour period
N/A N=30 Estrogen Sensitivity and Ovulatory Dysfunction in Obesity
Obesity · Infertility
Primary: Luteinizing Hormone Pulse Amplitude — 2.73; 1.12 IU/L
Phase 3 N=17 Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolescent Males With Hypogonadotropic Hypogonadism (HH) (MK-8962-043)
Hypogonadotropic Hypogonadism
Primary: Change From Baseline in Log-Transformed Testicular Volume (TV) to Week 64 — 1.5; 14.5 mL
Phase 3 N=121 Fat Mediated Modulation of Reproductive and Endocrine Function in Young Athletes
Exercise-related Amenorrhea
Primary: Change in Lumbar Bone Mineral Density — 0.025; 0.008; 0.012 g/cm^2 — p=0.039